Use of recombinant factor VII in cardiac surgery.
The off-label use of recombinant human coagulation factor VIIa has been increasing to a number of different treatment areas since its original approval in 1999. Several US patents describe claims for FVIIa utilization in nonhemophilia patients, treatment of bleeding due to trauma, as a means to reverse major bleeding, including intracranial bleeding, induced from fibrinolytic therapy as well as a patent for using FVIIa in the treatment of bleeding for patients with bleeding disorders not caused by hemophilia, but rather bleeding disorders due to thrombocytopenia, platelet disorders, and von Willebrand's disease. Bleeding after cardiac surgery remains a serious complication that can increase both morbidity and mortality. We review the off-label usage of recombinant factor VIIa as a hemostatic agent that may help control bleeding following cardiac surgery.
University of Illinois at Chicago and Medical Director, Cardiovascular Thoracic Surgery, Weiss Memorial Hospital, 4646 N Marine Dr., Chicago, IL, 60640, USA.
Mark
M
Elizalde
Leonid
L
Slobodskoy
Michael
M
Diodato
James
J
Chang
Edgar G
EG
Chedrawy
D001791:Blood Platelet Disorders / Q000188:drug therapy*; D006348:Cardiac Surgical Procedures / Q000009:adverse effects / Q000379:methods*; D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D056687:Off-Label Use; D011994:Recombinant Proteins / Q000627:therapeutic use
D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa